Delayed Reaction: BioMarin Rises On Pegvaliase Data
This article was originally published in Scrip
BioMarin Pharmaceutical Inc. has bounced back from a stock price slump that occurred after it reported that pegvaliase, the company's second therapy to treat phenylketonuria (PKU), met the primary endpoint in a Phase III clinical trial, but failed to meet a key secondary endpoint.
You may also be interested in...
Keeping Track: Thumbs Up For Doptelet And Palynziq, Thumbs Down For Methylene Blue MMX And Meloxicam
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: US FDA Approves Sickle Cell Therapy Endari; Array Submits Binimetinib Again
The latest drug development news and highlights from our FDA Performance Tracker.
BioMarin Expects 30% Markdown For Orphan Pediatric Drug Brineura
Fast US approval of ultra-rare pediatric disease drug Brineura (cerliponase alfa), with an annual list price of $702,000, is a victory for the company, but approval for restricted pediatric population compared to Europe raised questions.